Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02363387 · ClinicalTrials.gov registry record · NA

Suppression of HIV 1 RNA in People Living With HIV

A NA study of HIV, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
102
Enrollment target
1
Study location

NCT02363387 is a NA study of HIV that has completed, run by Johns Hopkins University. The registered enrollment target is 102 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02363387, a NA study of HIV, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

The investigators propose to evaluate a novel incentive intervention to promote suppression of viral load in people living with HIV that will employ empirically-based parameters that have been proven critical to the effectiveness of incentive interventions. Participants (N = 200) from medical clinics that serve adults living with HIV in Baltimore will be randomly assigned to an Incentive or a Usual Care Control group. Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years. Usual Care Control participants will only receive the standard HIV medical care offered in their clinic. Assessments will be conducted every 3 months throughout the two years of treatment and every 6 months throughout the year following treatment. The primary outcome measure will be the percentage of participants that have undetectable viral loads at the 3-month assessments conducted throughout the 2-year intervention period. Secondary measures will include adherence to HIV care and post-treatment outcomes. The investigators will also assess moderators and mediators of the effects of the incentives on the suppression of viral load, and conduct cost-effectiveness and cost-benefit analyses. If the incentive intervention maintains suppressed viral load and is economically sound, it could be used to improve the health of adults living with HIV, reduce health care costs, and reduce HIV transmission in the community.

Conditions Studied

Interventions

  • BEHAVIORAL Incentives for Viral Suppression
  • BEHAVIORAL Standard HIV Medical Care

Study Locations (1)

Maryland

  • Center for Learning and Health, Johns Hopkins Bayview Medical Campus, 5200 Eastern Ave., Suite W142 - Baltimore

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2015-11
Est. Completion 2021-03
Phase NA

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT02363387

The ClinicalTrials.gov registry entry for NCT02363387 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (77% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Incentives for Viral Suppression is the first listed.

NCT02363387 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT02363387 about?

NCT02363387 is a clinical study titled "Suppression of HIV 1 RNA in People Living With HIV". The investigators propose to evaluate a novel incentive intervention to promote suppression of viral load in people living with HIV that will employ empirically-based parameters that have been proven critical to the effectiveness of incentive interventions. Participants (N = 200) from medical clinic...

What is the current status of trial NCT02363387?

This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2015-11. Estimated completion is 2021-03.

What conditions does trial NCT02363387 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT02363387?

The interventions under investigation include: Incentives for Viral Suppression (BEHAVIORAL), Standard HIV Medical Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT02363387?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02363387 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.